For cohort 2, CA125, HE4, and MUC1 were increased in early-stage ovarian cancer whereas FOLR1 was equivalent between early-stage ovarian cancer and controls (Fig. 2). This evidence concerns the gene MUC16 and ovarian carcinoma.